Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365701 · ClinicalTrials.gov registry record · Phase 2
Study of Motilitone to Treat Functional Dyspepsia
A Phase 2 study of Dyspepsia, sponsored by Dong-A ST Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02365701: Completed Phase 2 study of Dyspepsia, sponsored by Dong-A ST Co..
NCT02365701 is a Phase 2 study of Dyspepsia that has completed, run by Dong-A ST Co.. The registered enrollment target is 45 participants, below the 73-participant average among 11 other Dyspepsia trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365701, a Phase 2 study of Dyspepsia, has completed, sponsored by Dong-A ST Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Motilitone 30mg
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
What the finished NCT02365701 record still lists
NCT02365701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 73-participant average among 11 other Dyspepsia trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Dyspepsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02365701 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02365701 about?
NCT02365701 is a clinical study titled "Study of Motilitone to Treat Functional Dyspepsia". This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.
What is the current status of trial NCT02365701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-06. Estimated completion is 2018-02.
What conditions does trial NCT02365701 study?
This clinical trial studies the following conditions: Dyspepsia.
What interventions are being tested in trial NCT02365701?
The interventions under investigation include: Placebo (DRUG), Motilitone 30mg (DRUG).
Who is sponsoring clinical trial NCT02365701?
This trial is sponsored by Dong-A ST Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365701 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyspepsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02365701's enrollment target sits among peer trials
45 10th of 11 higher than 2 of 11 other Dyspepsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyspepsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Visible Abdominal Distension
RECRUITING · NA
-
Zypan Functional Dyspepsia
RECRUITING · NA
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
High Resolution Gastric Mapping and Gastroduodenal Manometry
RECRUITING · NA
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
Famotidine and Antacids for Treatment of Dyspepsia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia